SCHEMBL177284

SCHEMBL177284

CCCOc1ccc(B(O)O)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
CASP1 P29466 1/20 0.40
HTT P42858 1/20 0.40
CASP7 P55210 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
THRA P10827 1/20 0.39
THRB P10828 1/20 0.39
PDE4D Q08499 1/20 0.39
LPL P06858 4/20 0.38
LIPG Q9Y5X9 4/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL177383 0.92 THRA (0.44) THRATHRBLPLLIPGENPP2
SCHEMBL29953148 0.92 THRA (0.44) THRATHRBLPLLIPGENPP2
SCHEMBL29950781 0.90 THRA (0.49) ALDH1A1THRATHRBLPLLIPG
SCHEMBL8220595 0.89 THRA (0.51) ALDH1A1THRATHRBLPLLIPG
SCHEMBL7514162 0.89 THRA (0.51) ALDH1A1THRATHRBLPLLIPG
SCHEMBL6657948 0.89 THRA (0.51) ALDH1A1THRATHRBLPLLIPG
SCHEMBL7789283 0.89 THRA (0.51) ALDH1A1THRATHRBLPLLIPG
SCHEMBL29737220 0.89 THRA (0.51) ALDH1A1THRATHRBLPLLIPG
SCHEMBL8351 0.86 KDM1A (0.46) ALDH1A1USP2HTTPDE4DLPL
SCHEMBL29825639 0.86 KDM1A (0.46) ALDH1A1USP2HTTPDE4DLPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820860-B1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2025-10-15 EP disclosed
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 LIEBER INSTITUE, INC (US) 2024-05-28 US disclosed
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ALTAVANT SCIENCES GMBH 2023-09-19 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20210205305-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2021-07-08 US disclosed
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INSTITUTE, INC 2021-05-13 US disclosed
US-10946018-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ROIVANT SCIENCES GMBH (CH) 2021-03-16 US disclosed
US-20200237760-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ROIVANT SCIENCES GMBH (CH) 2020-07-30 US disclosed
US-10660893-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ROIVANT SCIENCES, GmbH (CH) 2020-05-26 US disclosed
CN-110563615-A Water/alcohol soluble micromolecule hole transport material and preparation method thereof 南昌航空大学 2019-12-13 CN disclosed
EP-2073816-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2009-07-01 EP disclosed
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY DISCOVERY, INC. (US) 2009-04-16 US disclosed
WO-2008063300-A2 BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed
WO-2007051133-A2 SUBSTITUTED THIAZOLES AND THEIR USE MUTSUBISHI TANABE PHARMA CORPORATION (JP) 2007-05-03 WO disclosed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed
US-6197217-B1 EXHIBIT A NEGATIVE DIELECTRIC ANISOTROPY VALUE, HAVE AN EXTREMELY HIGH VOLTAGE HOLDING RATIO AND A LOW THRESHOLD VOLTAGE, SMALL DEPENDENCY ON TEMPERATURE, HARDLY EXHIBIT SMECTIC PHASE; EXCELLENT IN MISCIBILITY WITH OTHER LC'S CHISSO CORPORATION (JP) 2001-03-06 US disclosed
EP-0959061-A1 3,3'-DIFLUOROBIPHENYL DERIVATIVES, LIQUID CRYSTAL COMPOSITIONS, AND LIQUID CRYSTAL DISPLAY ELEMENTS CHISSO CORPORATION (JP) 1999-11-24 EP disclosed
US-5977105-A Compounds ASTRA PHARMAEUTICALS LTD. (GB) 1999-11-02 US disclosed
EP-0865431-A2 COMPOUNDS Astra Pharmaceuticals Limited (GB) 1998-09-23 EP disclosed
WO-1997020815-A1 COMPOUNDS ASTRA PHARMACEUTICALS LTD. (GB) 1997-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139456-A1 PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN5A, SCN2A MAPT 1531/4885KDM4E 3022/4885ALDH1A1 3396/4885
US-10660893-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A MAPT 4256/4885KDM4E 2437/4885ALDH1A1 433/4885
US-20200237760-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A MAPT 4256/4885KDM4E 2437/4885ALDH1A1 433/4885
US-20210205305-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A MAPT 4256/4885KDM4E 2437/4885ALDH1A1 433/4885
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 MAPT 2853/4885KDM4E 1655/4885ALDH1A1 444/4885
US-11759462-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A MAPT 4256/4885KDM4E 2437/4885ALDH1A1 433/4885
US-20070060573-A1 Acyltryptophanols FSHR, NPY1R, NPY2R MAPT 4047/4885KDM4E 2399/4885ALDH1A1 3830/4885
US-11993581-B2 Pyridazine compounds for inhibiting Nav1.8 SCN8A, SCN5A, SCN2A MAPT 1531/4885KDM4E 3022/4885ALDH1A1 3396/4885
US-10946018-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A MAPT 4256/4885KDM4E 2437/4885ALDH1A1 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.